Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company that develops therapeutics for people with serious muscle diseases. Its FORCE platform is built on antibody fragment (Fab)-oligonucleotide conjugates that target muscle tissue. Its lead programs are DYNE-251 for Duchenne muscular dystrophy (exon 51 skipping) and DYNE-101 for myotonic dystrophy type 1. It also has a program for facioscapulohumeral muscular dystrophy (FSHD).